AstraZeneca's Evusheld Retains Neutralizing Activity Against Omicron Variant In Studies

LONDON (dpa-AFX) - AstraZeneca's (AZN.L, AZN) Evusheld, a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron variant, the company

Related Keywords

Washington ,United States ,London ,City Of ,United Kingdom , ,Emergency Use Authorization ,Astrazeneca ,Evusheld ,Etains ,Neutralizing ,Activity ,Against ,Micron ,Variant ,Studies ,